Stocksigma LogoStocksigma Logo

USFDA Accepts Review for Zydus and Formycon Keytruda Biosimilar FYB206

The USFDA accepted the Biologics License Application for FYB206, a proposed biosimilar to Keytruda (pembrolizumab), marking the first publicly announced

USFDA Accepts Review for Zydus and Formycon Keytruda Biosimilar FYB206

Zydus Lifesciences Ltd 路 Press Release 路 13 Oct 2026, 3:20 pm

USFDA Accepts Review for Zydus and Formycon Keytruda Biosimilar FYB206 The USFDA accepted the Biologics License Application for FYB206, a proposed biosimilar to Keytruda (pembrolizumab), marking the first publicly announced acceptance for a Keytruda biosimilar. Developed without comparative Phase III efficacy trials via an agreed USFDA pathway, the dossier is also submitted to Health Canada, with an FDA decision expected in Q3'27. Zydus holds exclusive commercialization rights in the US and Canada, triggering a milestone payment to partner Formycon. Keytruda generated worldwide sales of USD 31.7B in 2025 and USD 16.40B in 1H'26.

Original exchange filing (PDF)

More announcements from Zydus Lifesciences Ltd

All Zydus Lifesciences Ltd announcements